Abstract:Background: The role of R-2-hydroxyglutarate (R-2HG), which is derived from mutant isocitrate dehydrogenase 1/2 (IDH1/2) enzymes, is controversial in myeloid malignancies. Although confirmed to promote leukemogenesis, R-2HG has recently been reported to exert anti-tumor activity in leukemia and glioma.Methods: Microarray and GSEA (gene set enrichment analysis) were used to identify core regulators in R-2HG-induced tumor cell death. To confirm the occurrence of necroptosis, we employed fluorescent apoptosis/necrosis (FAN) assay, Co-immunoprecipitation (Co-IP) and transmission electron microscopy.Findings: Here, we found that R-2HG increased the expression of receptor-interacting protein kinase 1 (RIPK1) and induced RIPK1-dependent necroptosis, thereby inhibiting the proliferation of malignant myeloid cells. Moreover, during the early stages of R-2HG treatment, higher levels of necroptosis was observed in comparison with apoptosis. The occurrence of R-2HG-induced necroptosis was independent of apoptosis and the G0/G1 cell cycle arrest. Additionally, the increased RIPK1 expression could be induced by the hypoexpression of lysine demethylase 2B (KDM2B), an α-KG-dependent dioxygenase. Furthermore, the downregulation of KDM2B could inhibit the proliferation of malignant myeloid cells via triggering necroptosis. We also found that low RIPK1 expression was significantly associated with a shorter overall survival, larger percentage of bone marrow blasts, and higher risk of leukemic transformation in 122 patients with myelodysplastic syndrome.Interpretation: Our study showed that R-2HG induces RIPK1-dependent necroptosis via the inhibition of KDM2B in malignant myeloid cells. Thus, KDM2B may represent a potential therapeutic target for myeloid malignancies.Funding Statement: This work was supported by grants from National Natural Science Foundation of China Grants (81970117, 81470290, and 81800121). Declaration of Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paperEthics Approval Statement: Sample collection and analysis were approved by the Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine, and written informed consent was obtained from all patients. All studies were approved by the Ethics Committee for Laboratory Animals of the First Affiliated Hospital, Zhejiang University School of Medicine.

RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcome

Development of Potent and Selective RIPK1 Degraders with In Vivo Efficacy for Cancer Treatment

SUPPLEMENTARY DATA FIGURES from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

R-2-Hydroxyglutarate Induces RIPK1-Dependent Necroptosis Via Inhibition of KDM2B in Myeloid Malignancies

A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death

RIPK1 inhibitor Cpd-71 attenuates renal dysfunction in cisplatin-treated mice via attenuating necroptosis, inflammation and oxidative stress.

RIPK2: A Promising Target for Cancer Treatment

Development of a RIPK1 degrader to enhance antitumor immunity

The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade

Data from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development

Discovery of Potent Necroptosis Inhibitors Targeting RIPK1 Kinase Activity for the Treatment of Inflammatory Disorder and Cancer Metastasis.

25 years of research put RIPK1 in the clinic

Tumor-intrinsic and Immune Modulatory Roles of Receptor-Interacting Protein Kinases

RIPK1 Dephosphorylation and Kinase Activation by PPP1R3G/PP1γ Promote Apoptosis and Necroptosis.

Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity

Differential Roles of RIPK1 and RIPK3 in TNF-induced Necroptosis and Chemotherapeutic Agent-Induced Cell Death.

"RIPping" off Pancreas Cancer's Blockage of Immune Surveillance

The resurrection of RIP kinase 1 as an early cell death checkpoint regulator-a potential target for therapy in the necroptosis era

RIP1-Dependent and Independent Effects of Necrostatin-1 in Necrosis and T Cell Activation

RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment